Collegium Pharma (COLL) Tops Q2 EPS by $1.43
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- SanDisk shares fall on election and chip sector pressure
- After-Hours Movers: QCOM, COHR, APP, HUBS, SNAP, FSLY, FIG, ZG, BROS, CDE
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
Collegium Reports Strong Q2 Results with Cash Balance Growing to Over $200 Million
August 5, 2021 4:01 PM EDTXtampza® ER Market Share Grew to 31.5% of the Oxycodone Extended-Release Market in June 2021
Net Income of $72.8 Million and Adjusted EBITDA of $40.1 Million
Full-Year 2021 Product Revenue Guidance Updated
Conference Call Scheduled for Today at 4:30 p.m. ET
STOUGHTON, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty... More



